{"denoms":[{"counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"94"},{"groupId":"BG005","value":"54"},{"groupId":"BG006","value":"54"},{"groupId":"BG007","value":"54"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"16"},{"groupId":"BG010","value":"43"},{"groupId":"BG011","value":"39"},{"groupId":"BG012","value":"430"}],"units":"Participants"}],"groups":[{"description":"Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).","id":"BG000","title":"Part A: Dabrafenib 75 mg + Trametinib 2 mg"},{"description":"Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.","id":"BG001","title":"Part B: Dabrafenib 75 mg + Trametinib 1 mg"},{"description":"Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.","id":"BG002","title":"Part B: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.","id":"BG003","title":"Part B: Dabrafenib 150 mg + Trametinib 1.5 mg"},{"description":"Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.","id":"BG004","title":"Part B: Dabrafenib 150 mg + Trametinib 2 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"BG005","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.","id":"BG006","title":"Part C: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.","id":"BG007","title":"Part C: Dabrafenib 150 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"BG008","title":"Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"BG009","title":"Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"BG010","title":"Part D: Dabrafenib 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"BG011","title":"Part D: Dabrafenib 150 mg + Trametinib 2 mg"},{"description":"Total of all reporting groups","id":"BG012","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"16.04","value":"52.8"},{"groupId":"BG001","spread":"7.28","value":"48.2"},{"groupId":"BG002","spread":"13.24","value":"54.2"},{"groupId":"BG003","spread":"12.09","value":"52.2"},{"groupId":"BG004","spread":"12.99","value":"52.4"},{"groupId":"BG005","spread":"15.19","value":"51.8"},{"groupId":"BG006","spread":"14.70","value":"49.9"},{"groupId":"BG007","spread":"11.85","value":"55.9"},{"groupId":"BG008","spread":"12.39","value":"51.8"},{"groupId":"BG009","spread":"17.04","value":"53.1"},{"groupId":"BG010","spread":"14.57","value":"52.8"},{"groupId":"BG011","spread":"14.08","value":"56.7"},{"groupId":"BG012","spread":"13.74","value":"52.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"56"},{"groupId":"BG005","value":"25"},{"groupId":"BG006","value":"24"},{"groupId":"BG007","value":"20"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"18"},{"groupId":"BG011","value":"14"},{"groupId":"BG012","value":"197"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"38"},{"groupId":"BG005","value":"29"},{"groupId":"BG006","value":"30"},{"groupId":"BG007","value":"34"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"8"},{"groupId":"BG010","value":"25"},{"groupId":"BG011","value":"25"},{"groupId":"BG012","value":"233"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"92"},{"groupId":"BG005","value":"52"},{"groupId":"BG006","value":"54"},{"groupId":"BG007","value":"53"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"16"},{"groupId":"BG010","value":"43"},{"groupId":"BG011","value":"39"},{"groupId":"BG012","value":"407"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"}]}],"title":"African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"3"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}